Skip to main content

Table 2 Patients’ characteristics according to Ki67 groups

From: Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage ‘pure’ and ‘mixed’ lobular breast cancer

Patients’ characteristics Patients (%) p-value
Ki67 < 6 % [N = 171] 6 % < Ki67 ≤ 21 % [N = 177] Ki67 > 21 % [N = 19]
Menopausal status     
 Premenopausal 50 (29.2) 47 (26.6) 9 (47.4) 0.16
 Postmenopausal 121 (70.8) 130 (73.4) 10 (52.6)  
Performance status (ECOG)     0.35
 0 163 (95.3) 162 (91.5) 18 (94.7)
 1–2 8 (4.7) 15 (8.5) 1 (5.3)
Type of surgery     
 Conservative surgery 120 (70.2) 113 (63.8) 10 (52.6) 0.20
 Mastectomy 51 (29.8) 64 (36.2) 9 (47.4)  
Sentinel lymph-node biopsy     
 No 92 (53.8) 105 (59.3) 14 (73.7) 0.20
 Yes 79 (46.2) 72 (40.7) 5 (26.3)  
Histological subtype     
 Pure lobular 119 (69.6) 129 (72.9) 12 (63.2) 0.72
 Ductal-lobular 48 (28.1) 43 (24.3) 7 (36.8)  
 Others 4 (2.3) 5 (2.8) 0 (0)  
T Descriptor according to TNM [7° Edition]     
 1 115 (67.3) 93 (52.5) 6 (31.5) 0.01
 2 43 (25.1) 60 (33.9) 11 (57.9)  
 3 11 (6.4) 17 (9.6) 1 (5.3)  
 4 2 (1.2) 7 (4.0) 1 (5.3)  
Lymph-nodes status     
 Negative 111 (64.9) 92 (52.0) 10 (52.6) 0.06
 Positive 56 (32.7) 74 (41.7) 9 (47.4)  
 Unknown 4 (2.3) 11 (6.2) 0 (0)  
Estrogen receptor status     
 Negative 6 (3.5) 3 (1.7) 2 (10.5) 0.29
 Positive 164 (95.9) 173 (97.7) 17 (89.5)  
 Unknown 1 (0.6) 1 (0.6) 0 (0)  
Progesterone receptor status     
 Negative 20 (11.7) 14 (7.9) 5 (26.3) 0.14
 Positive 144 (84.2) 157 (88.7) 13 (68.4)  
 Unknown 7 (4.1) 6 (3.4) 1 (5.3)  
HER2 status     
 Negative 124 (72.5) 118 (66.7) 11 (57.8) 0.01
 Positive 4 (2.3) 12 (6.8) 4 (21.1)  
 Unknown 43 (25.1) 47 (26.6) 4 (21.1)  
Histological grade     
 1 47 (27.5) 20 (11.3) 0 (0) <0.0001
 2 57 (33.3) 87 (49.2) 9 (47.4)  
 3 15 (8.8) 33 (18.6) 6 (31.6)  
 Unknown 52 (30.4) 37 (20.9) 4 (21.1)  
Vascular invasion     
 Absent 105 (61.4) 102 (57.6) 3 (15.8) <0.0001
 Present 26 (15.2) 45 (25.4) 10 (52.6)  
 Unknown 40 (23.4) 30 (16.9) 6 (31.6)  
Multifocality     
 Absent 131 (76.6) 137 (77.4) 16 (84.2) 0.48
 Present 38 (22.2) 38 (21.5) 2 (10.5)  
 Unknown 2 (1.2) 2 (1.1) 1 (5.3)  
Adjuvant hormonotherapy     
 No 20 (11.7) 12 (6.8) 5 (26.3) 0.02
 Yes 151 (88.3) 165 (93.2) 14 (73.7)  
Adjuvant chemotherapy     
 No 111 (64.9) 102 (57.6) 1 (5.3) <0.0001
 Yes 60 (34.1) 75 (42.4) 18 (94.7)  
Adjuvant radiotherapy     
 No 48 (28.1) 54 (30.5) 8 (42.1) 0.48
 Yes 118 (69.0) 114 (64.4) 11 (57.9)  
 Unknown 5 (2.9) 9 (5.1) 0 (0)  
  1. Legend – Table 2: N number, p-value chi-square test, ECOG Eastern Cooperative Oncology Group